Table of Contents Author Guidelines Submit a Manuscript
Pain Research and Treatment
Volume 2012 (2012), Article ID 282981, 10 pages
http://dx.doi.org/10.1155/2012/282981
Review Article

Designing Opioids That Deter Abuse

1Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA 19140, USA
2Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
3Department of Anesthesiology, School of Medicine, Georgetown University, Washington, DC 20057, USA
4Kirax Corporation, Inc., Bonita Springs, FL 34134, USA
5NEMA Research Inc., 840 111th Avenue North, Naples, FL 34108, USA

Received 8 May 2012; Revised 7 August 2012; Accepted 21 August 2012

Academic Editor: Steven D. Passik

Copyright © 2012 Robert B. Raffa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Emergency department visits involving nonmedical use of selected prescription drugs-United States, 2004–2008,” Morbidity and Mortality Weekly Report, vol. 59, no. 23, pp. 705–709, 2010.
  2. Anon, “Controlled substances act, part B. Authority and criteria for classification of substances,” in 21 United States Code, D. E. Administration, Ed., Office of Diversion Control, Washington, DC, USA, 2004. View at Google Scholar
  3. SAMHSA, Results from the 2009 National Survey on Drug Use and Health: Detailed tables, http://oas.samhsa.gov/NSDUH/2k9NSDUH/tabs/Sect1peTabs54to58.pdf, 2010.
  4. APA, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, DC, USA, 4th edition, 2000.
  5. S. H. Budman, J. M. Grimes Serrano, and S. F. Butler, “Can abuse deterrent formulations make a difference? Expectation and speculation,” Harm Reduction Journal, vol. 6, pp. 8–15, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. F. Butler, S. H. Budman, A. Licari et al., “National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse,” Pharmacoepidemiology and Drug Safety, vol. 17, no. 12, pp. 1142–1154, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. N. P. Katz, E. H. Adams, H. Chilcoat et al., “Challenges in the development of prescription opioid abuse-deterrent formulations,” Clinical Journal of Pain, vol. 23, no. 8, pp. 648–660, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. T. J. Cicero, G. Wong, Y. Tian, M. Lynskey, A. Todorov, and K. Isenberg, “Co-morbidity and utilization of medical services by pain patients receiving opioid medications: Data from an insurance claims database,” Pain, vol. 144, no. 1-2, pp. 20–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. S. D. Passik, K. L. Kirsh, K. B. Donaghy, and R. K. Portenoy, “Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse,” Clinical Journal of Pain, vol. 22, no. 2, pp. 173–181, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. R. K. Portenoy, “Opioid therapy for chronic nonmalignant pain: a review of the critical issues,” Journal of Pain and Symptom Management, vol. 11, no. 4, pp. 203–217, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. L. R. Webster and R. M. Webster, “Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool,” Pain Medicine, vol. 6, no. 6, pp. 432–442, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. S. D. Comer, M. A. Sullivan, S. K. Vosburg, W. J. Kowalczyk, and J. Houser, “Abuse liability of oxycodone as a function of pain and drug use history,” Drug and Alcohol Dependence, vol. 109, no. 1–3, pp. 130–138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. J. P. Zacny, S. Gutierrez, and S. A. Bolbolan, “Profiling the subjective, psychomotor, and physiological effects of a hydrocodone/acetaminophen product in recreational drug users,” Drug and Alcohol Dependence, vol. 78, no. 3, pp. 243–252, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. J. P. Zacny and S. Gutierrez, “Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers,” Psychopharmacology, vol. 170, no. 3, pp. 242–254, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. T. J. Cicero, M. S. Ellis, and H. L. Surratt, “Effect of abuse-deterrent formulation of oxyContin,” New England Journal of Medicine, vol. 367, no. 2, pp. 187–189, 2012. View at Publisher · View at Google Scholar
  16. N. Katz, Clinical Studies of Abuse Deterrent Opioid Analgesics: Definitions, Current Approaches, and Critical Issues, IMMPACT-X, Arlington, Va, USA, 2009.
  17. T. J. Cicero, M. S. Ellis, A. Paradis, and Z. Ortbal, “Determinants of fentanyl and other potent μ opioid agonist misuse in opioid-dependent individuals,” Pharmacoepidemiology and Drug Safety, vol. 19, no. 10, pp. 1057–1063, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Passik and K. Kirsh, “Chemical coping: the clinical middle ground,” in Pain and Chemical Dependency, H. S. Smith and S. Passik, Eds., Oxford University Press, New York, NY, USA, 2008. View at Google Scholar
  19. Booth, A Brief History of Opium, 2010.
  20. American College of Physicians, Aberrant Drug-Related Behaviors, http://www.acponline.org/about_acp/chapters/az/aberrant.pdf, 2012.
  21. American Society of Addiction Medicine, Public Policy Statement: Definition of Addiction, http://www.asam.org/for-the-public/definition-of-addiction, 2011.
  22. A. P. Association, Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition (Text Revision), American Psychiatric Publishing, Arlington, Va, USA, 4th edition, 2000.
  23. American Academy of Pain Medicine, The American Pain Society, and The American Society of Addition Medicine, “Definitions related to the use of opioids for the treatment of pain,” Wisconsin Medical Journal, vol. 100, no. 5, pp. 28–29, 2001. View at Google Scholar
  24. M. Zamloot, W. Chao, L. L. Kang, J. Ross, and R. Fu, “Remoxy ®:A novel formulation of extended-release oxycodone developed using the ORADUR ® technology,” International Journal of Applied Research in Veterinary Medicine, vol. 10, no. 3, pp. 88–96, 2010. View at Google Scholar · View at Scopus
  25. Acura, Acuracet, http://acurapharm.com/products/acuracet-tablets/, 2010.
  26. Acura, Vycavert, http://acurapharm.com/products/vycavert-tablets/, 2010.
  27. Pharmaceutical, C. Central Nervous System, Product Pipeline, http://www.collegiumpharma.com/products/cns.html, 2010.
  28. Intellipharmaceutics, Rexista Oxycodone, http://www.intellipharmaceutics.com/oxycodone.cfm, 2010.
  29. J. Haddox, J. E. Henningfield, and R. Mannion, A new formulation of OxyContin (oxycodone HCl controlled-release) tablets, http://www.fda.gov/ohrms/DOCKETS/ac/08/slides/2008-4356s1-05-Purdue.pdf, 2008.
  30. TheraQuest, TheraQuest Bioscience, Inc's IND for abuse deterrent strong opioid (TQ-1015) accepted by FDA, BioSpace, http://www.biospace.com/news_story.aspx?NewsEntityId=117355, 2008.
  31. Anon, US orphan status for TheraQuest's TQ-1017, The Pharma Letter, http://www.thepharmaletter.com/file/41950/us-orphan-status-for-theraquests-tq-1017.html, 2005.
  32. TheraQuest, TheraQuest Biosciences, Inc., unveils new pain management product pipeline, Press release, http://www.biospace.com/news_story.aspx?NewsEntityId=185046, 2010.
  33. Labopharm, DDS-08B: Abuse/misuse-deterrent formulation of twice-daily oxycodone-acetaminophen, http://www.labopharm.com/default.aspx?id=217, 2010.
  34. N. Pharmaceuticals, EXALGO (hydromorphone HCl) Extended-Release Tablets CII, Joint Meeting Anesthetic and Life Support Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee 2009 September 23, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM183035.pdf, 2009.
  35. Pisgah, Therapeutic discovery grant accelerates investigational new drug with abuse deterrent technology, Press release, http://www.pisgahlabs.com/General/PressRelease.aspx, 2010.
  36. Egalet, Technology overview, http://www.egalet.com/index.dsp?area=7, 2009.
  37. D. Ridgway, M. Sopata, A. Burneckis, L. Jespersen, and C. Andersen, “Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study,” Journal of Pain and Symptom Management, vol. 39, no. 4, pp. 712–720, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. Anon, Embeda Package Insert, King Pharmacenticals, Inc, Bristol, Tenn, USA, 2009.
  39. Anon, Phase 2 results of investigational abuse-deterrent opioid ALO-01 presented by Alpharma, Medical News Today, http://www.medicalnewstoday.com/printerfriendlynews.php?newsid=85689, 2007.
  40. L. Webster, “Update on abuse-resistant and abuse-deterrent approaches to opioid formulations,” Pain Medicine, vol. 10, no. 2, pp. S124–S133, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. Anon, Talwin Nx Civ Package Insert, http://products.sanofi-aventis.us/talwin_nx/talwin_nx.pdf, 2008.
  42. Anon, Treatment with Suboxone Film: understanding the benefits, http://www.suboxone.com/patients/about_suboxone/Default.aspx, 2010.
  43. Acura, Acurox Tablets, http://acurapharm.com/products/acurox-without-niacin-tablets/, 2010.
  44. Anon, Guidance for Industry: Assessment of Abuse Potential of Drugs, U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Silver Spring, Md, USA, 2010.
  45. L. Gershell and J. J. Goater, “Making gains in pain,” Nature Reviews Drug Discovery, vol. 5, no. 11, pp. 889–890, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Akbik, S. F. Butler, S. H. Budman, K. Fernandez, N. P. Katz, and R. N. Jamison, “Validation and clinical application of the screener and opioid assessment for patients with pain (SOAPP),” Journal of Pain and Symptom Management, vol. 32, no. 3, pp. 287–293, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. S. F. Butler, K. Fernandez, C. Benoit, S. H. Budman, and R. N. Jamison, “Validation of the revised screener and opioid assessment for patients with pain (SOAPP-R),” Journal of Pain, vol. 9, no. 4, pp. 360–372, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. S. F. Butler, S. H. Budman, K. Fernandez, and R. N. Jamison, “Validation of a screener and opioid assessment measure for patients with chronic pain,” Pain, vol. 112, no. 1-2, pp. 65–75, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. S. F. Butler, C. Benoit, S. H. Budman et al., “Development and validation of an opioid attractiveness scale: a novel measure of the attractiveness of opioid products to potential abusers,” Harm Reduction Journal, vol. 3, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. F. Berrendero, B. L. Kieffer, and R. Maldonado, “Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in μ-opioid receptor knock-out mice,” Journal of Neuroscience, vol. 22, no. 24, pp. 10935–10940, 2002. View at Google Scholar · View at Scopus
  51. E. M. Sellers, R. Schuller, M. K. Romach, and G. L. Horbay, “Relative abuse potential of opioid formulations in Canada: a structured field study.,” Journal of Opioid Management, vol. 2, no. 4, pp. 219–227, 2006. View at Google Scholar · View at Scopus
  52. B. L. Kieffer, “Opioids: first lessons from knockout mice,” Trends in Pharmacological Sciences, vol. 20, no. 1, pp. 19–26, 1999. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Rosenberg, “Drug abuse in oral and maxillofacial training programs,” Journal of Oral and Maxillofacial Surgery, vol. 44, no. 6, pp. 458–462, 1986. View at Google Scholar · View at Scopus
  54. C. F. Ward, G. C. Ward, and L. J. Saidman, “Drug abuse in anesthesia training programs. A survey: 1970 through 1980,” Journal of the American Medical Association, vol. 250, no. 7, pp. 922–925, 1983. View at Publisher · View at Google Scholar · View at Scopus
  55. H. D. Silsby, D. J. Kruzich, and M. R. Hawkins, “Fentanyl citrate abuse among health care professionals,” Military Medicine, vol. 149, no. 4, pp. 227–228, 1984. View at Google Scholar · View at Scopus
  56. N. D. Volkow, T. A. McLellan, J. H. Cotto, M. Karithanom, and S. R. B. Weiss, “Characteristics of opioid prescriptions in 2009,” Journal of the American Medical Association, vol. 305, no. 13, pp. 1299–1301, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. S. F. Butler, K. C. Fernandez, A. Chang et al., “Measuring attractiveness for abuse of prescription opioids,” Pain Medicine, vol. 11, no. 1, pp. 67–80, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. B. L. Wilsey, S. Fishman, C. S. Li, J. Storment, and A. Albanese, “Markers of abuse liability of short- vs long-acting opioids in chronic pain patients: a randomized cross-over trial,” Pharmacology Biochemistry and Behavior, vol. 94, no. 1, pp. 98–107, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. E. C. O'Connor and A. N. Mead, “Tramadol acts as a weak reinforcer in the rat self-administration model, consistent with its low abuse liability in humans,” Pharmacology Biochemistry and Behavior, vol. 96, no. 3, pp. 279–286, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. J. L. Katz and S. R. Goldberg, “Preclinical assessment of abuse liability of drugs,” Agents and Actions, vol. 23, no. 1-2, pp. 18–26, 1988. View at Google Scholar · View at Scopus
  61. M. E. Abreu, G. E. Bigelow, L. Fleisher, and S. L. Walsh, “Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans,” Psychopharmacology, vol. 154, no. 1, pp. 76–84, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. W. W. Stoops, K. W. Hatton, M. R. Lofwall, P. A. Nuzzo, and S. L. Walsh, “Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies,” Psychopharmacology, vol. 212, no. 2, pp. 193–203, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. S. M. Evans, E. J. Cone, and J. E. Henningfield, “Arterial and venous cocaine plasma concentrations in humans: relationship to route of administration, cardiovascular effects and subjective effects,” Journal of Pharmacology and Experimental Therapeutics, vol. 279, no. 3, pp. 1345–1356, 1996. View at Google Scholar · View at Scopus
  64. H. F. Hill, B. A. Coda, A. Tanaka, and R. Schaffer, “Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects,” Anesthesia and Analgesia, vol. 72, no. 3, pp. 330–336, 1991. View at Google Scholar · View at Scopus
  65. J. Stauffer, B. Setnik, M. Sokolowska, M. Romach, F. Johnson, and E. Sellers, “Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study,” Clinical Drug Investigation, vol. 29, no. 12, pp. 777–790, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. J. P. Schneider, M. Matthews, and R. N. Jamison, “Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?” CNS Drugs, vol. 24, no. 10, pp. 805–810, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. K. B. Stoller, G. E. Bigelow, S. L. Walsh, and E. C. Strain, “Effects of buprenorphine/naloxone in opioid-dependent humans,” Psychopharmacology, vol. 154, no. 3, pp. 230–242, 2001. View at Publisher · View at Google Scholar · View at Scopus
  68. E. C. Strain, K. Stoller, S. L. Walsh, and G. E. Bigelow, “Effects of buprenorphine versus buprenorphine/naloxone tablets in non- dependent opioid abusers,” Psychopharmacology, vol. 148, no. 4, pp. 374–383, 2000. View at Google Scholar · View at Scopus
  69. K. Mammen and J. Bell, “The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence,” Expert Opinion on Pharmacotherapy, vol. 10, no. 15, pp. 2537–2544, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. S. L. Walsh, P. A. Nuzzo, M. R. Lofwall, and J. R. Holtman, “The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers,” Drug and Alcohol Dependence, vol. 98, no. 3, pp. 191–202, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. X. Ruan, T. Chen, J. Gudin, J. P. Couch, and S. Chiravuri, “Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature,” Journal of Opioid Management, vol. 6, no. 4, pp. 300–303, 2010. View at Publisher · View at Google Scholar · View at Scopus